ARTICLE | Financial News

GenSight now eying Euronext

July 9, 2016 12:28 AM UTC

Gene therapy company GenSight Biologics S.A. (Paris, France) is proposing to raise about EUR 40 million ($44.3 million) in a listing on Euronext Paris. The company is targeting a price range of EUR 7.80-EUR 9.20 and expects to complete the offering next week.

In April, GenSight withdrew a proposed NASDAQ listing, citing market conditions. The company had filed in 2015 to raise up to $100 million. ...